Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
448 Leser
Artikel bewerten:
(2)

Senior data and technology leaders cite better decision-making as the primary aim of data modernization, says new MIT Technology Review Insights report

Finanznachrichten News

CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- A new report by MIT Technology Review Insights explores how data strategies and modernization initiatives misaligned with the overall business strategy-or too narrowly focused on AI-leave substantial business value on the table.

Insights

The report, "Modernizing data with strategic purpose," is produced in partnership with Thoughtworks and draws on a global survey of 350 senior data and technology leaders along with in-depth interviews conducted with experts on data strategy and modernization from firms including ExxonMobil, The Crown Estate, Payback, and Thoughtworks.

The key findings are as follows:

  • AI isn't the only reason companies are modernizing the data estate.Better decision-making is the primary aim of data modernization, with nearly half (46%) of executives citing this among their three top drivers. Support for AI models (40%) and for decarbonization (38%) are also major drivers of modernization.
  • Data strategy is too often siloed from business strategy. While only a small share (22%) of surveyed organizations lack a fully developed data strategy, no more than 39% say their data strategy is in complete alignment with the key objectives of the business. Data teams need to do more to bring other business units and functions into strategy discussions.
  • Data strategy paves the road to modernization. It is probably no coincidence that most organizations (71%) that have undertaken a data modernization in the past two years have had a data strategy in place for longer than that. Modernization goals require buy-in from the business, and implementation decisions need strategic guidance, lest they lead to added complexity or duplication.
  • Top data pain points are data quality and timeliness. Executives point to substandard data (cited by 41%) and untimely delivery (33%) as the facets of their data operations most in need of improvement. Incomplete or inaccurate data leads enterprise users to question data trustworthiness.This helps explain why the most common modernization measure taken by our respondents' organizations in the past two years has been to review and upgrade data governance (cited by 45%).

"Leaders highlight data modernization's focus on improving decision-making, driven by factors such as AI and decarbonization. However, a gap exists as organizations struggle to align data strategy with broader business goals," says Laurel Ruma, global director of custom content for MIT Technology Review. "By reviewing and upgrading data governance, organizations can improve operations, enhance data quality, and build trust."

"Only a third of leaders reported complete alignment of their data strategy with business strategy goals, which is key to organizations maximizing the business impact from their data," says Danilo Sato, global head of technology for data and AI for Thoughtworks. "By applying effective and scalable data engineering practices alongside a modern data platform, organizations will start realizing how data plus AI as a force multiplier can be a powerful driver of growth and competitive advantage."

To download the report, click here.

For more information please contact:

Natasha Conteh
Head of communications
MIT Technology Review Insights
natasha.conteh@technologyreview.com

About MIT Technology Review Insights

MIT Technology Review Insights is the custom publishing division of MIT Technology Review, the world's longest-running technology magazine, backed by the world's foremost technology institution-producing live events and research on the leading technology and business challenges of the day. Insights conducts qualitative and quantitative research and analysis in the US and abroad and publishes a wide variety of content, including articles, reports, infographics, videos, and podcasts. And through its growing MIT Technology Review Global Insights Panel, Insights has unparalleled access to senior-level executives, innovators, and entrepreneurs worldwide for surveys and in-depth interviews.

Logo - https://mma.prnewswire.com/media/831545/MIT_Technology_Review_Insights_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/senior-data-and-technology-leaders-cite-better-decision-making-as-the-primary-aim-of-data-modernization-says-new-mit-technology-review-insights-report-302113175.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.